Merck closes in on allergy trifecta with MK-8237 Phase IIb data

21:50 EST 5 Mar 2014 | SCRIP

Merck reported data for the two MK-8237 doses tested in the trial on 4 March in a late-breaker session at the American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego. Hendrik Nolte, Merck's allergy immunotherapy clinica...

Original Article: Merck closes in on allergy trifecta with MK-8237 Phase IIb data

NEXT ARTICLE

More From BioPortfolio on "Merck closes in on allergy trifecta with MK-8237 Phase IIb data"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Allergies
Latest News Clinical Trials Research Drugs Reports Corporate
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pulmonary
Latest News Clinical Trials Research Drugs Reports Corporate
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Advertisement

Searches Linking to this Story